The Science Behind Retatrutide's Triple Mechanism Each of retatrutide's three receptor targets contributes unique metabolic benefits: GIP Receptor Activation: Enhances insulin secretion in response to food intake Influences fat metabolism and storage patterns Modulates bone metabolism and cardiovascular function Complements GLP-1 effects for improved glycemic control GLP-1 Receptor Activation: Stimulates insulin release while suppressing glucagon Slows gastric emptying to extend satiety Reduces appetite through central nervous system pathways Provides cardiovascular protective effects Glucagon Receptor Activation: Increases energy expenditure and metabolic rate Promotes fat oxidation and lipolysis Helps prevent metabolic adaptation during weight loss Balances the anabolic effects of insulin signaling This triple-action approach explains why retatrutide demonstrated remarkable results in phase 2 clinical trials, with participants experiencing up to 24.2% body weight reduction at 48 weeks [4]

A comprehensive 2025 review in Molecules compiled evidence that the AEDG peptide has been studied for its influence on expression of key antioxidant genes, including SOD2 (superoxide dismutase 2), CAT (catalase), and HMOX1 (heme oxygenase-1) (8)
In experimental contexts, Epithalon is explored for its influence on cellular longevity pathways, melatonin regulation, and genomic stability mechanisms
None Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources
[1] [2] Despite marketing claims found online, there is no substantial clinical evidence supporting BPC-157's safety or efficacy in humans
Evaluating a longevity protocol meaningfully requires investing in the data